Inventor · disambiguated record
Chen Zhang
Also filed as: ZHANG CHEN · ZHANG CHEN-YU
17 granted patents·52 pending applications·37 citations·filing 2000–2025
89Inventor score
Files withXIZANG HAISCO PHARMACEUTICAL CO LTD25SICHUAN HAISCO PHARMACEUTICAL CO LTD11HAISCO PHARMACEUTICALS PTE LTD5UNIV SICHUAN5BETH ISRAEL HOSPITAL2
Top patents by PatentIndex Score
69 records- 0192US11807635B2Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereofHAISCO PHARMACEUTICALS PTE LTD·Filed 2022·Granted Nov 7, 2023·5 cites·12 claims
- 0290US7649014B2Genipin derivatives and uses thereofBETH ISRAEL HOSPITAL·Filed 2005·Granted Jan 19, 2010·10 cites·10 claims
- 0386US11542266B1Substituted piperidines as BTK inhibitorsHAISCO PHARMACEUTICALS PTE LTD·Filed 2021·Granted Jan 3, 2023·3 cites·19 claims
- 0486US11053260B2Tri-cycle compound and applications thereofFUJIAN COSUNTER PHARMACEUTICAL CO LTD·Filed 2018·Granted Jul 6, 2021·4 cites·18 claims
- 0580US8093288B2Genipin derivatives and uses thereofZHANG CHEN-YU·Filed 2009·Granted Jan 10, 2012·5 cites·14 claims
- 0675US11014964B2Peptide amide compound and preparation method and medical use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2018·Granted May 25, 2021·2 cites·13 claims
- 0774US12365673B2Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereofHAISCO PHARMACEUTICALS PTE LTD·Filed 2023·Granted Jul 22, 2025·0 cites·6 claims
- 0873US6365796B1Transgenic UCP2 knockout mouse and use thereofBETH ISRAEL HOSPITAL·Filed 2000·Granted Apr 2, 2002·8 cites·15 claims
- 0973US2025042930A1Method for preparing aryl carbon glycoside compound including gliflozin drugUNIV SICHUAN·Filed 2024·Application pending·0 cites
- 1073US2025059226A1Sulfinate glycosyl donor, method for preparing same, and use thereofUNIV SICHUAN·Filed 2024·Application pending·0 cites
- 1168US2025340555A1Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use ThereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 1268US2025364567A1High-performance lithium battery current collector and preparation method therefor, and conductive paste and preparation method thereforBLUEGLOWNANO TECH LIMITED·Filed 2023·Application pending·0 cites
- 1367US2025059186A1Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use ThereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1462US2025263426A1Pde4b inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1562US2025042936A1Method for glycosylation modification of proteins and/or polypeptidesUNIV SICHUAN·Filed 2024·Application pending·0 cites
- 1661US2025326765A1Pde4b inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1759US2025171436A1Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use ThereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1859US2025145627A1METTL3 Inhibitor and Composition, and Application of Same in MedicineXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1959US2025340532A1Heterocyclic compound ccr4 inhibitor and user thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2059US2024383917A1Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicineXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2158US2025000988A1Epha2 bicyclic peptide ligand and conjugate thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2258US2025346571A1Bicyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2357US2025195485A1Propionic acid derivative and medical use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2457US2025333410A1Compound for inhibiting or degrading bcl6 and use thereof in pharmaceuticsXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2557US2019274615A1Systems and method for detecting, diagnosing, and/or treatment of disorders and conditionsUNIV KHALIFA SCIENCE & TECHNOLOGY·Filed 2019·Application pending·0 cites
- 2656US2024391937A1Bicyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2756US2024208932A1Arylamino derivative estrogen receptor modulator and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2856US2024043416A1Salt and crystal form of ha inhibitor compoundSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2956US2025034168A1Nitrogen-containing heterocyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3056US2025382289A1Pyrazolopyridine derivative and application thereof in medicineXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 3155US12492215B2Pyrrolotriazine compounds acting as MNK inhibitorJUMBO DRUG BANK CO LTD·Filed 2022·Granted Dec 9, 2025·0 cites·20 claims
- 3255US2024067633A1Ketohexokinase inhibitor and use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3355US2025222116A1Parp-1 degradation agent and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3455US2024343720A1Aak1 inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3555US2025084101A1Compound for inhibiting and degrading irak4, and pharmaceutical composition and pharmaceutical application thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 3654US2024124470A1Five-membered ring derivative and medical use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3754US2024368204A1Small molecular cd73 antagonist and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3853US12202812B2Glycosyl donor, preparation method therefor, and use thereofUNIV SICHUAN·Filed 2020·Granted Jan 21, 2025·0 cites·6 claims
- 3953US10221185B2Crystal form of substituted aminopyran derivativekSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2016·Granted Mar 5, 2019·0 cites·18 claims
- 4053US2023144619A1Salt of arylaminopurine derivative, preparation method therefor and use thereofCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2021·Application pending·0 cites
- 4153US2025215008A1Preparation and use of quinazolinone derivative as kinase inhibitorHAISCO PHARMACEUTICAL GROUP CO LTD·Filed 2023·Application pending·0 cites
- 4253US2023265107A1Pb2 inhibitor, and preparation method therefor and use thereofSICHUAN HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 4353US2025171417A1Heterocyclic derivative, and composition and pharmaceutical use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 4452US2024317736A1Deuterated derivative as atx inhibitor, and application thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 4552US2024400586A1Heteroaryl derivative parp inhibitor and use thereofHAISCO PHARMACEUTICAL GROUP CO LTD·Filed 2022·Application pending·0 cites
- 4651US2025154119A1Glycosyl donor, preparation method therefor, and use thereofUNIV SICHUAN·Filed 2025·Application pending·0 cites
- 4751US2024408085A1Compound for degradation of bcl-2 family proteins and medical application thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 4851US2024018147A1Salt of compound for degrading btk, crystal form thereof, and use thereof in medicineHAISCO PHARMACEUTICALS PTE LTD·Filed 2021·Application pending·0 cites
- 4950US11634424B2Diazaindole derivative and use thereof as CHK1 inhibitorMEDSHINE DISCOVERY INC·Filed 2020·Granted Apr 25, 2023·0 cites·13 claims
- 5050US10327691B2Systems and method for detecting, diagnosing, and/or treatment of disorders and conditionsUNIV KHALIFA SCIENCE & TECHNOLOGY·Filed 2016·Granted Jun 25, 2019·0 cites·16 claims
Showing the top 50 of 69 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →